viite: EudraCT-numero 2005-004253-10 Tyypin 2 diabetesta sairastavien maksansiirtopotilaiden rasvamaksan hoito insuliiniherkistajalla (rosiglitatsoni)

Trial Profile

viite: EudraCT-numero 2005-004253-10 Tyypin 2 diabetesta sairastavien maksansiirtopotilaiden rasvamaksan hoito insuliiniherkistajalla (rosiglitatsoni)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 May 2011

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Fatty liver; Hyperglycaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top